Key Highlights
- Tempest Therapeutics (Nasdaq: TPST) led gainers, closing up 59% at $1.20 on a CAR-T licensing deal with Senlang.
- Xenetic Biosciences (Nasdaq: XBIO) fell 49% to $2.19 despite announcing a Merger with Santersus AG to form Santersus Bio.
- Aethlon Medical (Nasdaq: AEMD) agreed to merge into North Immunology, trading as NRTX, alongside a $180 million financing.
- Longeveron (Nasdaq: LGVN) and Cellectis (Nasdaq: CLLS) both retreated on a missed Phase 2b endpoint and a Barclays downgrade, respectively.
Ten Names in Motion
Ten biotech and pharmaceutical stocks were in motion in the same session, driven by a mix of licensing deals, merger announcements, clinical trial results and analyst rating changes. Gainers were led by early-stage cell-therapy and oncology developers, while two names retreated sharply following a trial miss and a portfolio-strategy downgrade.
Tempest Therapeutics (Nasdaq: TPST)
Tempest Therapeutics (Nasdaq: TPST) was the session's biggest gainer, closing up 59% at $1.20 after securing an exclusive option agreement with Senlang for a CD7-targeted lentiviral vector platform and in vivo CAR-T portfolio. The deal adds a Phase 1 BCMA/GPRC5D dual-targeting candidate for multiple myeloma, which has shown early in vivo CAR-T generation and expansion with no Grade 3 or higher CRS or ICANS reported as of August 25.
NanoViricides (NYSE: NNVC)
NanoViricides (NYSE: NNVC) closed up 14% at $1.20 after saying patient administration will begin next week in a Phase 2 trial in the Democratic Republic of Congo testing oral NV-387 chewable gummies against Ebola, including the Bundibugyo virus type. The program pairs a single-arm Phase 2a safety cohort with a randomized Phase 2b efficacy evaluation.
PRF Technologies (Nasdaq: PRFX)
PRF Technologies (Nasdaq: PRFX) rose 12% to $1.01 on plans to adapt its GridFeed AI energy management architecture toward hyperscale Data Center optimization, extending momentum from a September 9 restructuring that made GridFeed a dedicated corporate unit for data center alliances.
BlossomHill Therapeutics (Nasdaq: BLSM)
BlossomHill Therapeutics (Nasdaq: BLSM) gained 18% to $26.25 after reporting Phase 1/2 SOLARA data showing a 45% objective response rate and 88% disease control rate for oral OMNI-EGFR candidate BH-30643 in EGFR C797S-positive NSCLC, a resistance setting with no approved targeted therapies.
Xenetic Biosciences (Nasdaq: XBIO)
Xenetic Biosciences (Nasdaq: XBIO) fell 49% to $2.19 despite announcing an all-stock merger with Santersus AG to form Santersus Bio, trading under the ticker SNTS. Santersus stockholders will hold approximately 85% of the combined company, with Xenetic shareholders retaining around 15% — dilution that appeared to outweigh the strategic rationale behind the combined company's NET-focused pipeline.
Artelo Biosciences (Nasdaq: ARTL)
Artelo Biosciences (Nasdaq: ARTL) declined 30% to $3.75 even as it released preclinical data showing once-daily oral ART27.13 matched semaglutide's roughly 20% weight reduction in obese mouse models, with the combination of the two therapies reaching about 40% total weight loss.
Aethlon Medical (Nasdaq: AEMD)
Aethlon Medical (Nasdaq: AEMD) agreed to a definitive all-stock merger with North Immunology alongside an intended $180 million private financing. The combined company will trade as North Immunology under the ticker NRTX, with North investors holding roughly 95.25% of the combined entity and Aethlon shareholders retaining 4.75% plus a Hemopurifier contingent value right.
Longeveron (Nasdaq: LGVN)
Longeveron (Nasdaq: LGVN) said its Phase 2b ELPIS II trial of laromestrocel in infants with hypoplastic left heart syndrome missed its primary endpoint, with right ventricular ejection fraction improvement at Month 12 of -0.7 percentage points versus placebo (p=0.8336). The company is now exploring strategic Options and implementing cost containment measures.
Cellectis (Nasdaq: CLLS)
Cellectis (Nasdaq: CLLS) was downgraded by Barclays from Overweight to Underweight, with the price target cut from $9.00 to $1.30, after the company discontinued its clinical CAR-T portfolio to pivot toward early-stage in vivo gene editing.
Nuvation Bio (NYSE: NUVB)
Nuvation Bio (NYSE: NUVB) secured FDA approval for a supplemental New Drug Application updating the label for IBTROZI with 49.7-month median duration of response data from the TRUST-I study in TKI-naive ROS1-positive NSCLC, arriving four months ahead of its scheduled PDUFA date with no new safety signals.
Wide Dispersion Across the Group
Across the ten names, catalysts ranged from early-stage licensing and merger activity to late-stage trial readouts and one-off analyst actions, underscoring the wide dispersion of outcomes that can appear in a single Trading session across small- and mid-cap biotech and pharma stocks.
Which stock had the largest gain?
Tempest Therapeutics (Nasdaq: TPST) led gainers, closing up 59% on its Senlang CAR-T licensing deal.
Which stock had the largest decline?
Xenetic Biosciences (Nasdaq: XBIO) fell the most, down 49%, despite announcing its merger with Santersus AG.
What linked several of these moves?
Multiple companies were reacting to CAR-T or cell-therapy strategy shifts — Tempest Therapeutics optioned a new platform, Cellectis discontinued its CAR-T portfolio, and Aethlon Medical is merging into a bispecific antibody developer.






Please wait processing your request...